Base-case cost-effectiveness results
| Trabectedin plus PLD | PLD | Difference | |
|---|---|---|---|
| Total costs (€, 2011) | 45573 | 23072 | 22501 |
| Cost of treatment (drug+administration) | |||
| Cost of AEs | 431 | 206 | |
| Cost of medical management | 18269 | 14069 | |
| LYG | 2.80 | 2.13 | 0.68 |
| QALY gained | 2.35 | 1.86 | 0.49 |
| ICER; €/LYG of trabectedin plus PLD vs PLD | 33335 | ||
| ICER; €/QALY gained of trabectedin plus PLD vs PLD | 45592 |
AE, adverse event; ICER, incremental cost-effectiveness ratio; LYG, life year gained; PLD, pegylated liposomal doxorubicin; QALY, quality-adjusted life year.